Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1359 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-12

Study Completion Date

2023-03-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection. The total study duration is up to 28 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial of Remdesivir in Adults With Severe COVID-19

NCT04257656

COVID-19 Remdesivir SARS-CoV-2

TERMINATED PHASE3

A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19

NCT05758519

COVID-19

UNKNOWN PHASE3

A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

NCT05689203

COVID-19

UNKNOWN PHASE2

A Trial of Remdesivir in Adults With Mild and Moderate COVID-19

NCT04252664

COVID-19 SARS-CoV-2

SUSPENDED PHASE3

A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants

NCT05458076

COVID-19

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild to Moderate COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RAY1216

Participants received 400mg RAY1216 tablet orally three times daily for 5 days.

Group Type EXPERIMENTAL

RAY1216

Intervention Type DRUG

RAY1216（tablet）

Placebo

Participants received 400mg placebo orally three times daily for 5 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo （tablet）

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RAY1216

RAY1216（tablet）

Intervention Type DRUG

Placebo

placebo （tablet）

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions.
2. Participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures.
3. Male or female participants aged 18-75 (including 18 and 75 years old).
4. Confirmed SARS-CoV-2 infection 120 hours prior to randomization.
5. Initial onset of COVID-19 symptoms/signs within 48 hours before randomization.
6. Fertile participants must agree to take effective contraceptive measures.

Exclusion Criteria

1. Patients with severe or critical COVID-19 who currently require hospitalization, or patients who are expected to develop into severe or critical disease and require hospitalization within 48h after randomization.
2. Difficulty swallowing or a history of gastrointestinal diseases that seriously affect drug absorption.
3. Active liver disease, or obvious abnormal liver function (ALT or AST ≥ 3ULN, or total bilirubin ≥ 2ULN).
4. WBC \>1ULN, or NEU \<0.5ⅹ109/L.
5. Receiving dialysis or have known moderate to severe renal impairment (eGFR\<60mL/min/1.73m2).
6. Other suspected or confirmed systemic infections.
7. Current or expected use of strong CYP3A4 inducers, inhibitors or medications that are highly dependent on CYP3A4 or CYP2C19 for clearance.
8. Prior or anticipated receipt of any vaccine within 28 days prior to enrollment and during study period.
9. Use of antivirals against SARS-CoV-2 within 7 days prior to enrollment.
10. Weight≤40kg.
11. Pregnant, lactating women or those with a positive pregnancy test (sterilized or postmenopausal women may not have a pregnancy test).
12. Previous administration with any investigational drug within 3 months before the study drug administration.
13. Participants who are judged by the investigator to be unsuitable to participate in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No